Alzheimer's disease - Recent biomarker developments in relation to updated diagnostic criteria

Clinica Chimica Acta

Volumn 449, Issue , 2015, Pages 3-8

  Höglund, Kina ^a   Fourier, Anthony ^b,c   Perret Liaudet, Armand ^b,c   Zetterberg, Henrik ^a,d   Blennow, Kaj ^a   Portelius, Erik ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b HOSPICES CIVILS DE LYON   (France)

^c LYON NEUROSCIENCE RESEARCH CENTER   (France)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Biomarker; Cerebrospinal fluid; Diagnosis; Tau; Amyloid

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; NEUROGRANIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT; TAU PROTEIN;

ALZHEIMER DISEASE; ANALYTIC METHOD; ARTICLE; BRAIN REGION; CLINICAL PRACTICE; DEMENTIA; DIAGNOSTIC VALUE; DISEASE COURSE; HUMAN; NERVE DEGENERATION; NERVE FIBER; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; PRODROMAL SYMPTOM; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; SYNAPSE; ANIMAL; CEREBROSPINAL FLUID;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BIOMARKERS; HUMANS; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 84940435386     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.01.041     Document Type: Article

References (126)

1. Serrano-Pozo A., Frosch M.P., Masliah E., Hyman B.T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011, 1:a006189.
2. Blennow K., Hampel H., Weiner M., Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010, 6:131-144.
3. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
4. Dubois B., Feldman H.H., Jacova C., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007, 6:734-746.
5. Dubois B., Feldman H.H., Jacova C., et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014, 13:614-629.
6. Masliah E., Mallory M., Alford M., et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 2001, 56:127-129.
7. Rosen C., Hansson O., Blennow K., Zetterberg H. Fluid biomarkers in Alzheimer's disease - current concepts. Mol Neurodegener 2013, 8:20.
8. Zetterberg H., Wilson D., Andreasson U., et al. Plasma tau levels in Alzheimer's disease. Alzheimers Res Ther 2013, 5:9.
9. Chiu M.J., Chen Y.F., Chen T.F., et al. Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer's disease. Hum Brain Mapp 2014, 35:3132-3142.
10. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006, 5:228-234.
11. Johansson P., Mattsson N., Hansson O., et al. Cerebrospinal fluid biomarkers for Alzheimer's disease: diagnostic performance in a homogeneous mono-center population. J Alzheimers Dis 2011, 24:537-546.
12. Andreasen N., Minthon L., Davidsson P., et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001, 58:373-379.
13. Landau S.M., Harvey D., Madison C.M., et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010, 75:230-238.
14. Shaw L.M., Vanderstichele H., Knapik-Czajka M., et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009, 65:403-413.
15. Sunderland T., Linker G., Mirza N., et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003, 289:2094-2103.
16. De Strooper B., Annaert W. Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci 2000, 113(Pt 11):1857-1870.
17. Zheng H., Koo E.H. Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegener 2011, 6:27.
18. Portelius E., Mattsson N., Andreasson U., Blennow K., Zetterberg H. Novel abeta isoforms in Alzheimer's disease - their role in diagnosis and treatment. Curr Pharm Des 2011, 17:2594-2602.
19. Perneczky R., Alexopoulos P., Kurz A. Soluble amyloid precursor proteins and secretases as Alzheimer's disease biomarkers. Trends Mol Med 2014, 20:8-15.
20. Portelius E., Brinkmalm G., Tran A., et al. Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluid. Exp Neurol 2010, 223:351-358.
21. Alcolea D., Carmona-Iragui M., Suarez-Calvet M., et al. Relationship between beta-secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease. J Alzheimers Dis 2014, 42:157-167.
22. Lewczuk P., Kamrowski-Kruck H., Peters O., et al. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry 2010, 15:138-145.
23. Brinkmalm G., Brinkmalm A., Bourgeois P., et al. Soluble amyloid precursor protein alpha and beta in CSF in Alzheimer's disease. Brain Res 2013, 1513:117-126.
24. Alexopoulos P., Tsolakidou A., Roselli F., et al. Clinical and neurobiological correlates of soluble amyloid precursor proteins in the cerebrospinal fluid. Alzheimers Dement 2012, 8:304-311.
25. Cuchillo-Ibanez I., Lopez-Font I., Boix-Amoros A., et al. Heteromers of amyloid precursor protein in cerebrospinal fluid. Mol Neurodegener 2015, 10:2.
26. Portelius E., Dean R.A., Andreasson U., et al. Beta-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces Abeta5-X peptides through alternative amyloid precursor protein cleavage. Alzheimers Res Ther 2014, 6:75.
27. Wong C.W., Quaranta V., Glenner G.G. Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related. Proc Natl Acad Sci U S A 1985, 82:8729-8732.
28. Glenner G.G., Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984, 120:885-890.
29. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 1985, 82:4245-4249.
30. Seubert P., Vigo-Pelfrey C., Esch F., et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992, 359:325-327.
31. Motter R., Vigo-Pelfrey C., Kholodenko D., et al. Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995, 38:643-648.
32. Buchhave P., Minthon L., Zetterberg H., Wallin A.K., Blennow K., Hansson O. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012, 69:98-106.
33. Visser P.J., Verhey F., Knol D.L., et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009, 8:619-627.
34. Skoog I., Davidsson P., Aevarsson O., Vanderstichele H., Vanmechelen E., Blennow K. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord 2003, 15:169-176.
35. Gustafson D.R., Skoog I., Rosengren L., Zetterberg H., Blennow K. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry 2007, 78:461-464.
36. Stomrud E., Hansson O., Blennow K., Minthon L., Londos E. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3years in healthy elderly. Dement Geriatr Cogn Disord 2007, 24:118-124.
37. Strozyk D., Blennow K., White L.R., Launer L.J. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003, 60:652-656.
38. Fagan A.M., Mintun M.A., Mach R.H., et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006, 59:512-519.
39. Hansson O., Zetterberg H., Buchhave P., et al. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 2007, 23:316-320.
40. Sauvee M., DidierLaurent G., Latarche C., Escanye M.C., Olivier J.L., Malaplate-Armand C. Additional use of Abeta(4)(2)/Abeta(4)(0) ratio with cerebrospinal fluid biomarkers p-tau and Abeta(4)(2) increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice. J Alzheimers Dis 2014, 41:377-386.
41. Brinkmalm G., Portelius E., Ohrfelt A., et al. An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid beta and amyloid precursor protein in human and cat cerebrospinal fluid. J Mass Spectrom 2012, 47:591-603.
42. Portelius E., Fortea J., Molinuevo J.L., Gustavsson M.K., Andreasson U., Sanchez-Valle R. The amyloid-beta isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer's disease. Mol Med Rep 2012, 5:1111-1115.
43. Portelius E., Tran A.J., Andreasson U., et al. Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res 2007, 6:4433-4439.
44. Portelius E., Westman-Brinkmalm A., Zetterberg H., Blennow K. Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J Proteome Res 2006, 5:1010-1016.
45. Portelius E., Zetterberg H., Andreasson U., et al. An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid. Neurosci Lett 2006, 409:215-219.
46. Portelius E., Brinkmalm G., Tran A.J., Zetterberg H., Westman-Brinkmalm A., Blennow K. Identification of novel APP/Abeta isoforms in human cerebrospinal fluid. Neurodegener Dis 2009, 6:87-94.
47. Drechsel D.N., Hyman A.A., Cobb M.H., Kirschner M.W. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell 1992, 3:1141-1154.
48. Ebneth A., Godemann R., Stamer K., Illenberger S., Trinczek B., Mandelkow E. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J Cell Biol 1998, 143:777-794.
49. Cuchillo-Ibanez I., Seereeram A., Byers H.L., et al. Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin. FASEB J 2008, 22:3186-3195.
50. Trinczek B., Ebneth A., Mandelkow E.M., Mandelkow E. Tau regulates the attachment/detachment but not the speed of motors in microtubule-dependent transport of single vesicles and organelles. J Cell Sci 1999, 112(Pt 14):2355-2367.
51. Goedert M., Spillantini M.G., Potier M.C., Ulrich J., Crowther R.A. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J 1989, 8:393-399.
52. Kolarova M., Garcia-Sierra F., Bartos A., Ricny J., Ripova D. Structure and pathology of tau protein in Alzheimer disease. Int J Alzheimers Dis 2012, 2012:731526.
53. Georgieff I.S., Liem R.K., Couchie D., Mavilia C., Nunez J., Shelanski M.L. Expression of high molecular weight tau in the central and peripheral nervous systems. J Cell Sci 1993, 105(Pt 3):729-737.
54. Goedert M., Spillantini M.G., Crowther R.A. Cloning of a big tau microtubule-associated protein characteristic of the peripheral nervous system. Proc Natl Acad Sci U S A 1992, 89:1983-1987.
55. Andreasen N., Blennow K. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin Neurol Neurosurg 2005, 107:165-173.
56. Blennow K., Zetterberg H., Fagan A.M. Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med 2012, 2:a006221.
57. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004, 1:213-225.
58. Blennow K., Lind B., Andersson E., Andreasen N. CSF-analyses in clinical diagnosis of Creutzfeldt-Jakob disease. a literature review and three cases from routine clinical practice. Lakartidningen 2001, 98:2446-2451.
59. Hesse C., Rosengren L., Andreasen N., et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 2001, 297:187-190.
60. Ost M., Nylen K., Csajbok L., et al. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 2006, 67:1600-1604.
61. Buerger K., Ewers M., Pirttila T., et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006, 129:3035-3041.
62. Tapiola T., Alafuzoff I., Herukka S.K., et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009, 66:382-389.
63. Hanger D.P., Byers H.L., Wray S., et al. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem 2007, 282:23645-23654.
64. Vanmechelen E., Vanderstichele H., Davidsson P., et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000, 285:49-52.
65. Tang W., Huang Q., Yao Y.Y., Wang Y., Wu Y.L., Wang Z.Y. Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature. J Neural Transm 2014, 121:1541-1553.
66. Kohnken R., Buerger K., Zinkowski R., et al. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 2000, 287:187-190.
67. Ishiguro K., Ohno H., Arai H., et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett 1999, 270:91-94.
68. Hu Y.Y., He S.S., Wang X., et al. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol 2002, 160:1269-1278.
69. Blennow K., Vanmechelen E., Hampel H. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 2001, 24:87-97.
70. Lewczuk P., Esselmann H., Otto M., et al. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging 2004, 25:273-281.
71. van Rossum I.A., Vos S.J., Burns L., et al. Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology 2012, 79:1809-1816.
72. Fagan A.M., Head D., Shah A.R., et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009, 65:176-183.
73. Mattsson N., Andreasson U., Persson S., et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 2011, 7:386-395. [e386].
74. Leinenbach A., Pannee J., Dulffer T., et al. Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-beta in cerebrospinal fluid. Clin Chem 2014, 60:987-994.
75. Korecka M., Waligorska T., Figurski M., et al. Qualification of a surrogate matrix-based absolute quantification method for amyloid-beta(4)(2) in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry. J Alzheimers Dis 2014, 41:441-451.
76. Carrillo M.C., Blennow K., Soares H., et al. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimers Dement 2013, 9:137-140.
77. McAvoy T., Lassman M.E., Spellman D.S., et al. Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry. Clin Chem 2014, 60:683-689.
78. Scheff S.W., Price D.A., Schmitt F.A., DeKosky S.T., Mufson E.J. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 2007, 68:1501-1508.
79. Baudier J., Deloulme J.C., Van Dorsselaer A., Black D., Matthes H.W. Purification and characterization of a brain-specific protein kinase C substrate, neurogranin (p17). Identification of a consensus amino acid sequence between neurogranin and neuromodulin (GAP43) that corresponds to the protein kinase C phosphorylation site and the calmodulin-binding domain. J Biol Chem 1991, 266:229-237.
80. Huang K.P., Huang F.L., Chen H.C. Characterization of a 7.5-kDa protein kinase C substrate (RC3 protein, neurogranin) from rat brain. Arch Biochem Biophys 1993, 305:570-580.
81. Thorsell A., Bjerke M., Gobom J., et al. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Brain Res 2010, 1362:13-22.
82. Kvartsberg H., Duits F.H., Ingelsson M., et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlated with cognitive decline in prodromal Alzheimer's disease. Alzheimers Dement 2015, [in press]. 10.1016/j.jalz.2014.10.009.
83. Laterza O.F., Modur V.R., Crimmins D.L., et al. Identification of novel brain biomarkers. Clin Chem 2006, 52:1713-1721.
84. Lee J.M., Blennow K., Andreasen N., et al. The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem 2008, 54:1617-1623.
85. Tarawneh R., D'Angelo G., Macy E., et al. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol 2011, 70:274-285.
86. Mroczko B., Groblewska M., Zboch M., et al. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease. J Alzheimers Dis 2015, 43:1031-1037.
87. Tarawneh R., Lee J.M., Ladenson J.H., Morris J.C., Holtzman D.M. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology 2012, 78:709-719.
88. Gresle M.M., Shaw G., Jarrott B., et al. Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis. J Neurosci Res 2008, 86:3548-3555.
89. Petzold A., Keir G., Green A.J., Giovannoni G., Thompson E.J. A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 2003, 278:179-190.
90. Rosengren L.E., Karlsson J.E., Karlsson J.O., Persson L.I., Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996, 67:2013-2018.
91. Norgren N., Rosengren L., Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res 2003, 987:25-31.
92. Rosengren L.E., Karlsson J.E., Sjogren M., Blennow K., Wallin A. Neurofilament protein levels in CSF are increased in dementia. Neurology 1999, 52:1090-1093.
93. Pijnenburg Y.A., Janssen J.C., Schoonenboom N.S., et al. CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls. Dement Geriatr Cogn Disord 2007, 23:225-230.
94. Sjogren M., Rosengren L., Minthon L., Davidsson P., Blennow K., Wallin A. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 2000, 54:1960-1964.
95. Hu Y.Y., He S.S., Wang X.C., et al. Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci Lett 2002, 320:156-160.
96. Brettschneider J., Petzold A., Sussmuth S.D., Ludolph A.C., Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 2006, 66:852-856.
97. Skillback T., Farahmand B., Bartlett J.W., et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology 2014, 83:1945-1953.
98. Petzold A., Keir G., Warren J., Fox N., Rossor M.N. A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia. Neurodegener Dis 2007, 4:185-194.
99. Vandermeeren M., Mercken M., Vanmechelen E., et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993, 61:1828-1834.
100. Blennow K., Wallin A., Agren H., Spenger C., Siegfried J., Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?. Mol Chem Neuropathol 1995, 26:231-245.
101. Wolozin B., Davies P. Alzheimer-related neuronal protein A68: specificity and distribution. Ann Neurol 1987, 22:521-526.
102. Vigo-Pelfrey C., Seubert P., Barbour R., et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology 1995, 45:788-793.
103. Johnson G.V., Seubert P., Cox T.M., Motter R., Brown J.P., Galasko D. The tau protein in human cerebrospinal fluid in Alzheimer's disease consists of proteolytically derived fragments. J Neurochem 1997, 68:430-433.
104. Zemlan F.P., Rosenberg W.S., Luebbe P.A., et al. Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins. J Neurochem 1999, 72:741-750.
105. Maccioni R.B., Lavados M., Guillon M., et al. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects. Neurobiol Aging 2006, 27:237-244.
106. Meredith J.E., Sankaranarayanan S., Guss V., et al. Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease. PLoS One 2013, 8:e76523.
107. Amadoro G., Corsetti V., Sancesario G.M., et al. Cerebrospinal fluid levels of a 20-22kDa NH2 fragment of human tau provide a novel neuronal injury biomarker in Alzheimer's disease and other dementias. J Alzheimers Dis 2014, 42:211-226.
108. Arai H., Terajima M., Miura M., et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol 1995, 38:649-652.
109. Borroni B., Gardoni F., Parnetti L., et al. Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. Neurobiol Aging 2009, 30:34-40.
110. Sjogren M., Davidsson P., Tullberg M., et al. Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001, 70:624-630.
111. Zhang Z., Song M., Liu X., et al. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease. Nat Med 2014, 20:1254-1262.
112. Sokolow S., Henkins K.M., Bilousova T., et al. Presynaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease. J Neurochem 2014, 10.1111/jnc.12991.
113. Henriksen K., Wang Y., Sorensen M.G., et al. An enzyme-generated fragment of tau measured in serum shows an inverse correlation to cognitive function. PLoS One 2013, 8:e64990.
114. De Strooper B. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev 2010, 90:465-494.
115. Johnson G.V. Tau phosphorylation and proteolysis: insights and perspectives. J Alzheimers Dis 2006, 9:243-250.
116. Chesser A.S., Pritchard S.M., Johnson G.V. Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease. Front Neurol 2013, 4:122.
117. Salloway S., Sperling R., Fox N.C., et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014, 370:322-333.
118. Coric V., van Dyck C.H., Salloway S., et al. Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 2012, 69:1430-1440.
119. Portelius E., Dean R.A., Gustavsson M.K., et al. A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. Alzheimers Res Ther 2010, 2:7.
120. Portelius E., Gustavsson M.K., Zetterberg H., Andreasson U., Blennow K. Evaluation of the performance of novel Abeta isoforms as theragnostic markers in Alzheimer's disease: from the cell to the patient. Neurodegener Dis 2012, 10:138-140.
121. Blennow K. Biomarkers in Alzheimer's disease drug development. Nat Med 2010, 16:1218-1222.
122. Hampel H., Frank R., Broich K., et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010, 9:560-574.
123. Asuni A.A., Boutajangout A., Quartermain D., Sigurdsson E.M. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007, 27:9115-9129.
124. Wischik C.M., Harrington C.R., Storey J.M. Tau-aggregation inhibitor therapy for Alzheimer's disease. Biochem Pharmacol 2014, 88:529-539.
125. Bulic B., Pickhardt M., Mandelkow E. Progress and developments in tau aggregation inhibitors for Alzheimer disease. J Med Chem 2013, 56:4135-4155.
126. Kontsekova E., Zilka N., Kovacech B., Novak P., Novak M. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res Ther 2014, 6:44.